Fabtech Technologies Cleanrooms Ltd
Incorporated in 2015, Fabtech Technologies Cleanrooms Limited is a global company specializing in turnkey engineering solutions for the pharmaceutical, biotech, and healthcare sectors.[1]
- Market Cap ₹ 313 Cr.
- Current Price ₹ 254
- High / Low ₹ 470 / 203
- Stock P/E 32.5
- Book Value ₹ 75.8
- Dividend Yield 0.79 %
- ROCE 21.6 %
- ROE 16.5 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 24.9% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 10.2% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Industrial Manufacturing Industrial Products
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 86 | 65 | 107 | 114 | 83 | 139 | 131 | |
| 80 | 64 | 101 | 101 | 75 | 123 | 119 | |
| Operating Profit | 6 | 1 | 6 | 12 | 8 | 16 | 11 |
| OPM % | 7% | 2% | 5% | 11% | 10% | 11% | 9% |
| 1 | 0 | 0 | 0 | 1 | 1 | 2 | |
| Interest | 1 | 0 | 1 | 1 | 1 | 0 | 0 |
| Depreciation | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 6 | 0 | 5 | 11 | 7 | 16 | 12 |
| Tax % | 29% | -52% | 35% | 28% | 28% | 24% | |
| 4 | 1 | 3 | 8 | 5 | 12 | 10 | |
| EPS in Rs | 1,310.00 | 233.33 | 11.49 | 29.07 | 18.88 | 9.77 | 7.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 20% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 9% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 55% |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 15% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 12 | 12 |
| Reserves | 32 | 32 | 35 | 44 | 49 | 81 | 81 |
| 10 | 7 | 8 | 6 | 5 | 0 | 5 | |
| 21 | 25 | 32 | 23 | 24 | 24 | 18 | |
| Total Liabilities | 66 | 67 | 79 | 75 | 81 | 117 | 117 |
| 3 | 3 | 3 | 3 | 4 | 3 | 3 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 3 | 3 | 3 | 3 | 4 | 28 | 21 |
| 60 | 60 | 72 | 69 | 73 | 86 | 93 | |
| Total Assets | 66 | 67 | 79 | 75 | 81 | 117 | 117 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -9 | 4 | 3 | 8 | 4 | 2 | |
| 2 | -1 | -4 | -3 | -2 | -25 | |
| 7 | -3 | 1 | -4 | -2 | 24 | |
| Net Cash Flow | 1 | -1 | 0 | 1 | 0 | 1 |
| Free Cash Flow | -10 | 3 | 3 | 8 | 2 | 1 |
| CFO/OP | -123% | 354% | 67% | 84% | 84% | 39% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 188 | 236 | 172 | 149 | 203 | 132 |
| Inventory Days | 54 | 85 | 52 | 45 | 82 | 58 |
| Days Payable | 108 | 139 | 96 | 69 | 105 | 67 |
| Cash Conversion Cycle | 134 | 183 | 127 | 124 | 179 | 123 |
| Working Capital Days | 115 | 152 | 94 | 101 | 156 | 128 |
| ROCE % | 2% | 13% | 25% | 15% | 22% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Installed Manufacturing Space sq. ft. |
|
||
| Consolidated Order Book ₹ Crores |
|||
| Total Employee Count Number |
|||
| Number of Clients Nodes |
|||
| Order Pipeline (Leads) ₹ Crores |
|||
| Panel Manufacturing Capacity Utilization % |
|||
| Revenue Mix - Non-Pharma % |
|||
| Revenue Mix - Pharma % |
|||
Documents
Announcements
-
Corporate Announcement On Order Booking And Update
11 Apr - March 2026 orders of ₹9.82 crore; order book at ₹199.21 crore, with ₹482 crore under consideration.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Filed Regulation 74(5) compliance certificate for quarter ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
30 Mar - Fabtech completed acquisition of Advantek Air Systems Private Limited, completion notified March 30, 2026.
- Closure of Trading Window 27 Mar
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 16 Mar
Annual reports
Concalls
-
Nov 2025Transcript PPT
-
Jun 2025TranscriptPPT
-
Mar 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
Business Overview[1]
Fabtech Technologies Cleanrooms specializes in manufacturing and providing end-to-end solutions for pre-engineered and pre-fabricated modular panels and doors for cleanrooms. These cleanrooms are used in pharmaceutical, healthcare, and biotech sectors and adhere to global regulatory standards like ISO and FDA. The company offers services including design, engineering, manufacturing, quality assurance, installation, and validation.